Independent director
Independent opinions on matters related to the sixth meeting of the eighth board of directors
As an independent director of Xiamen Amoytop Biotech Co.Ltd(688278) (hereinafter referred to as “the company”), in accordance with the relevant provisions of the company law, the securities law, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange, the governance standards of listed companies and the articles of association, after carefully reviewing the relevant matters of the sixth meeting of the eighth board of directors of the company, we express our independent opinions as follows:
1、 Proposal on the company’s profit distribution plan in 2021
The company’s profit distribution plan for 2021 complies with the requirements of the company law, the articles of association and other requirements. The plan fully takes into account the company’s current profitability, capital demand and industry characteristics, which is conducive to the stable development of the company and does not harm the interests of the company’s shareholders, especially the small and medium-sized shareholders. Agree to this profit distribution plan and submit it to the general meeting of shareholders for deliberation.
2、 Proposal on re employment of accounting firm
Rongcheng Certified Public Accountants (special general partnership) has many years of audit service experience in listed companies and can meet the requirements of the company’s annual financial and internal control audit. The review and voting procedures of this renewed accounting firm comply with the provisions of relevant laws and regulations, and there is no damage to the interests of the company and the rights and interests of minority shareholders. It is agreed to continue to employ Rongcheng Certified Public Accountants (special general partnership) as the company’s audit institution in 2022 and submit the matter to the general meeting of shareholders for deliberation.
3、 Proposal on internal control evaluation report of the company in 2021
During the reporting period, the company actively promoted the construction of enterprise internal control standard system, established a relatively complete internal control system, and ensured the standardized operation of the company’s general meeting of shareholders, the board of directors, the board of supervisors and other institutions and the effectiveness of the internal control system. We have carefully reviewed the report on the company’s internal control system in 2021, which objectively reflects the current situation of the company’s internal control system and its operation.
4、 Proposal on the special report on the deposit and actual use of the company’s raised funds in 2021
We have checked the drafts related to the deposit and use of the raised funds and carefully reviewed the special report on the raised funds issued by the company. We believe that the report has been true, accurate, complete and in accordance with the requirements of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of the raised funds of listed companies and the Listing Rules of Shanghai Stock Exchange on the science and innovation board Timely disclosed the deposit and actual use of the company’s raised funds. The company has made special account storage and special use of the raised funds. There is no case of changing the purpose of the raised funds in a disguised manner and damaging the interests of shareholders, nor is there any case of illegal use of the raised funds.
5、 Proposal on remuneration scheme for senior management of the company
The remuneration scheme of the company’s senior managers is determined according to the business situation and performance appraisal indicators and in combination with the remuneration level of the company’s industry. Adhering to the principles of openness, fairness and impartiality, it is conducive to the sustainable, stable and healthy development of the company, and there is no damage to the interests of the company and shareholders (especially small and medium-sized shareholders). We agree with the proposal.
6、 Proposal on using some idle self owned funds for cash management
On the premise of complying with national laws and regulations, ensuring the safety of investment funds and not affecting the normal operation of the company, the company uses some idle self owned funds for cash management, which is conducive to improving the efficiency of fund use and obtaining investment income, and there is no situation that damages the interests of the company and shareholders (especially minority shareholders). It is agreed that the company will use idle self owned funds of no more than RMB 300 million (including this amount) for cash management.
(there is no text on this page, which is the signature page of the independent opinions of Xiamen Amoytop Biotech Co.Ltd(688278) independent directors on matters related to the sixth meeting of the eighth board of directors)
Signature: Signature:
Name: Jiang Xiaohui Name: Zhou Kefu
Signature: Name: Liu Qi
specific date
